Novo Nordisk (CPSE:NOVO B) Lands Global Rights To Weekly Oral GLP 1 Candidate

• Novo Nordisk (CPSE:NOVO B) signed an exclusive global license agreement with Hengrui Pharma for HRS-1596, a once-weekly oral GLP-1/GIP dual agonist.
• The deal grants Novo Nordisk rights outside China, Hong Kong, Macao, and Taiwan, while Hengrui retains those territories.
• HRS-1596 adds a next-generation, once-weekly oral metabolic therapy candidate to Novo Nordisk's pipeline for future global development.
• Novo Nordisk's HRS-1596 licensing move is important. However, it should sit alongside other key issues in your investment thinking. We have also flagged 2 warning signs (1 major) for Novo Nordisk.

For readers interested in more ways to consider the long-term demand behind these kinds of therapies, explore 87 AI infrastructure stocks.

Novo Nordisk operates as a large pharmaceuticals group focused on researching, manufacturing, and distributing treatments. This licensing move fits squarely within its push to expand its portfolio of metabolic therapies through partnerships rather than only in-house discoveries.

3 things going right for Novo Nordisk that this headline doesn't cover.

Why does a once-weekly oral GLP-1/GIP like HRS-1596 matter for Novo Nordisk?

An oral, once-weekly GLP-1/GIP candidate gives Novo Nordisk another way to meet demand from patients who prefer pills over injections in obesity and diabetes care. HRS-1596 slots alongside CagriSema and existing semaglutide products as part of a broader metabolic franchise rather than a single product bet.

How does this licensing deal fit with Novo Nordisk’s recent partnerships and pipeline moves?

The agreement with Hengrui sits next to collaborations with Siemens Healthineers, Orbis Medicines and Anthropic, plus Phase 3 work on CagriSema, Sogroya, FREHEMGO and Zenagamtide. Together, these projects indicate Novo Nordisk is using external platforms and alliances to widen exposure across cardiometabolic, liver, haemophilia, growth and pain treatments while still leaning on GLP-1 science.

Does this change the Novo Nordisk Narrative investors have been using?

The Narrative already centers on GLP-1 demand, pricing and patent risks, and R&D efforts to diversify beyond semaglutide. HRS-1596 supports the “expanded product launches and adjacent indications” aspect of that storyline, but it does not remove concerns about price erosion, generic competition or high capital spending highlighted in the risk section.

See how these catalysts shape Novo Nordisk's path to a DKK310 fair value.

What is the key sign that will show whether HRS-1596 is genuinely important for Novo Nordisk?

The most telling marker will be how quickly HRS-1596 moves from phase 1 readiness into later stage trials, including any future disclosure of phase 2 or phase 3 start dates and target indications. Clear development timelines and trial designs would help show whether management views this as a core GLP-1 pillar or a more optional add-on.

Add Novo Nordisk to your Watchlist and get alerts as these catalysts play out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com